ABSTRACT G protein-coupled receptor (GPR) 17 is a P2Y-like receptor that responds to both uracil nucleotides (as UDP-glucose) and cysteinyl-leukotrienes (cysLTs, as LTD 4 ). By bioinformatic analysis, two distinct binding sites have been hypothesized to be present on GPR17, but little is known on their putative cross-regulation and on GPR17 desensitization/resensitization upon agonist exposure. In this study, we investigated in GPR17-expressing 1321N1 cells the cross-regulation between purinergic-and cysLT-mediated responses and analyzed GPR17 regulation after prolonged agonist exposure. Because GPR17 receptors couple to G i proteins and adenylyl cyclase inhibition, both guanosine 5Ј-O-(3-[
Introduction
The P2Y-like, G protein-coupled receptor (GPR) GPR17 is structurally and phylogenetically related to previously identified P2Y receptors (P2YRs) for extracellular nucleotides and to the cysteinyl-leukotriene 1 and 2 receptors (CysLT 1 and CysLT 2 , respectively), which respond to arachidonic acid-derived cysteinyl-leukotrienes (cysLTs).
Previously, it has been demonstrated that on both the native Ceruti et al., 2011; Fumagalli et al., 2011) and the recombinant receptors (Ciana et al., 2006; Lecca et al., 2008; Pugliese et al., 2009; Temporini et al., 2009; Calleri et al., 2010) , GPR17 acts as a classic ligandactivated GPR that responds to both uracil nucleotides (UDP, UDP-glucose, and UDP-galactose; Jacobson and Boeynaems, 2010) and cysLTs (LTC 4 , LTD 4 , and LTE 4 ) ( Bä ck, 2002) . One group has confirmed independently that GPR17 responds to purinergic uracil ligands (Benned-Jensen and Rosenkilde, 2010) , whereas Maekawa et al. (2009) have suggested GPR17 as a constitutive, negative regulator for CysLT 1 . Bioinformatic data have suggested the presence of two distinct binding sites on GPR17, one for nucleotides and the other for cysLT (Parravicini et al., 2008 ; however, it is still unclear if GPR17 predominantly behaves as a purinergic receptor that may be able to modulate responses to cysLTs through a protein-protein interaction mechanism.
Previously, it was demonstrated that the presence of the GPR17 transcript and protein is restricted to very early stages of differentiation in oligodendrocyte precursor cells (OPCs) and is segregated completely from mature myelin proteins to the point that mature myelinating oligodendrocytes no longer express GPR17 (Lecca et al., 2008; Ceruti et al., 2011; Fumagalli et al., 2011) . GPR17 endogenous ligands also have been found to promote OPC maturation (Lecca et al., 2008; Ceruti et al., 2011) . Therefore, these ligands first induce early precursor cells to undergo their differentiation by binding to GPR17; then, at a certain stage of OPC differentiation, they also trigger receptor desensitization with subsequent intracellular internalization and degradation, contributing to its removal from the cell membrane. A similar process has been associated with the specification of other cell lineages (e.g., erythrocytes), in which the down-regulation of membrane receptors for key trophic or differentiating factors has been proposed as necessary to allow cells to proceed toward terminal maturation (Walrafen et al., 2005) .
Desensitization is a common process that regulates the functional responsiveness of both P2YRs (Otero et al., 2000; Santiago-Pérez et al., 2001) and CysLTs (Winkler et al., 1988) . Heterologous regulation between P2YRs and CysLTs has been demonstrated in human monocyte/macrophage-like cells, in which the activation of P2YRs with ATP or UDP induced the desensitization of the CysLT 1 . In contrast, LTD 4 -induced CysLT 1 activation had no effect on the responses of P2YRs .
Although much has been learned about the cellular activation and regulation of each class of GPR17 ligand, studies still are being performed on the mechanisms of GPR17 crossregulation that lead to priming or desensitization. Therefore, the present study was undertaken to assess the possible interactions between the two putative GPR17 purinergic and cysLT binding sites in a recombinant GPR17 expression system and to characterize GPR17 homologous/heterologous desensitization/resensitization by cysLT and purinergic ligands.
The two classes of GPR17 ligands were demonstrated to interact with each other through allosteric modulation. Furthermore, both UDP-glucose and LTD 4 induced time-dependent receptor desensitization and internalization with kinetic rates comparable for the two classes of ligands. After induction of the desensitization, receptor responsiveness was recovered with kinetic values that were typical of GPRs. Finally, the activation of the GPR17 purinergic site by UDPglucose (but not vice versa) induced the heterologous desensitization of LTD 4 -mediated responses, with resensitization kinetics comparable to those of the purinergic site.
These results suggest the existence of a functional cross-talk between cysLT and purinergic sites on GPR17 and that the latter have a hierarchy in producing desensitizing signals. Cell Culture and Stable Transfection. Astrocytoma cells (1321N1) were seeded onto 75-cm 2 flasks (10 6 cells) in Dulbecco's modified Eagle's medium and then transfected with pcDNA 3.1-human GPR17 (hGPR17) or with the plasmid alone using the calcium phosphate precipitation method, as described previously (Pugliese et al., 2009) .
Materials and Methods

Chemicals and
RNA Isolation and Reverse Transcription Polymerase Chain Reaction. Total RNA (1 g) was reverse-transcribed using a QuantiTect transcription kit (QIAGEN, Valencia, CA) in a total volume of 20 l. Two microliters of the reverse transcription mixture was used for polymerase chain reaction (PCR). The PCR mixture contained a total volume of 25 l consisting of 200 M of each deoxynucleotide triphosphate, 300 nM forward and reverse primers (Table 1 ), 1.5 mM MgCl 2 , and 1 U of AmpliTaq Gold (Applied Biosystems, Foster City, CA) in an equipped buffer. Thermal cycling was performed with an initial denaturation of 5 min at 94°C and followed by 35 cycles of 1 min at 95°C, 30 s at annealing temperatures, and 1 min at 72°C, with a terminal extension of 7 min at 72°C. PCR products were separated by agarose gel electrophoresis on 2.5% UltraPure agarose-Tris-borate EDTA gels (Invitrogen, Carlsbad, CA), which were visualized by ethidium bromide staining under UV light.
[ 35 S]GTP␥S Binding Assay. Control and transfected cells were homogenized in 5 mM Tris-HCl and 2 mM EDTA (pH 7.4) and then centrifuged at 48,000g for 15 min at 4°C. The resulting pellets (plasma membranes) were washed in 50 mM Tris-HCl and 10 mM MgCl 2 (pH 7.4) and then stored at Ϫ80°C until needed. Nucleotideor cysLT-stimulated [
35 S]GTP␥S binding assays in the membranes of cells expressing hGPR17 or pcDNA 3.1 were performed as described previously (Ciana et al., 2006; Pugliese et al., 2009; Calleri et al., 2010) in the absence or presence of nucleotides or cysLTs.
To determine the possible interaction between nucleotides or cysLTs, membranes were preincubated with LTD 4 (5 or 50 nM) or UDP-glucose (10 or 100 M) and then stimulated with different UDP-glucose or LTD 4 concentrations, respectively.
In some experiments, the effects of GPR17 antagonists on agonistmediated effects were evaluated. In particular, the adenosine-based P2Y 12-13 antagonist cangrelor (formerly AR-C69931MX; Marteau et al., 2003; Fumagalli et al., 2004; Srinivasan et al., 2009) Lynch et al., 1999; Heise et al., 2000) , which have been characterized previously and demonstrated to have an high affinity for GPR17 (Ciana et al., 2006; Pugliese et al., 2009 ), were used. The antagonists were added for 5 min before addition of UDP-glucose and LTD 4 to determine the inhibition of the agonist-mediated G protein activation.
Measurement of cAMP Levels. Intracellular cAMP levels were measured using a competitive protein binding method, as reported previously (Colotta et al., 2008; Trincavelli et al., 2008; The functional responses of purinergic and cysLT ligands on hGPR17 were evaluated by assessing their abilities to inhibit cAMP accumulation stimulated by 10 M forskolin (FK). Cells were stirred for 15 min with 10 M UDP-glucose or 10 nM LTD 4 . The reaction was terminated by the removal of the medium and the addition of 200 l of 0.4 N HCl. After 30 min, lysates were neutralized with 50 l of 4 N KOH, and the suspension was centrifuged at 800g for 5 min. For the determination of cAMP production, the cAMP binding protein, isolated from bovine adrenal glands, was incubated with [ 3 H]cAMP (2 nM), and 50 l of cell lysate or cAMP standard (0 -16 pmol) at 0°C for 150 min in a total volume of 300 l. The bound radioactivity was separated by rapid filtration through GF/C glass fiber filters (PerkinElmer Life and Analytical Sciences) and washed twice with 4 ml of 50 mM Tris-HCl (pH 7.4). The radioactivity was measured by liquid scintillation spectrometry.
For homologous and heterologous desensitization experiments, the cells were treated with UDP-glucose (100 nM to 100 M) or LTD 4 (0.5-100 nM) at different times (5-90 min). Then, cells were washed and stimulated with UDP-glucose (10 M) or LTD 4 (10 nM) for 15 min, and cAMP levels were quantified. In resensitization experiments, the cells were treated with UDP-glucose (100 M) or LTD 4 (100 nM) for 90 min to induce GPR17 desensitization, and then the cells were washed in the absence of agonists for 30 to 120 min.
Biotinylation Experiments. GPR17-transfected cells (1321N1) were seeded onto 100-mm 2 Petri dishes to reach 80% confluence. After 24 h, cells were biotinylated using 0.3 mg/ml sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3Јdithiopropionate (EZ-Link Sulfo-NHS-SSBiotin; Thermo Fisher Scientific, Waltham, MA) dissolved in phosphate-buffered saline (PBS) with 0.1 mM CaCl 2 and 1 mM MgCl 2 for 30 min at 4°C. The labeled cells were washed twice for 10 min with 50 mM glycine in Tris-buffered saline (25 mM Tris, 85 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , and 1 mM MgCl 2 ) to quench the free biotin. When required, cells were incubated subsequently in noncompleting medium in the absence or presence of 100 M UDP-glucose or 100 nM LTD 4 for 15 or 30 min. After being washed at 4°C with ice-cold PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 , the remaining biotin label on the surface was removed by incubating cells twice at 4°C with 50 mM dithiothreitol (DTT) in PBS with 0.1 mM CaCl 2 and 1 mM MgCl 2 for 15 min each time. DTT was neutralized with iodoacetamide (10 mM) in PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 , and cells then were lysed in buffer A, which contained 1% Triton X-100 and a protease inhibitor cocktail. After centrifugation (20,000g for 20 min at 4°C), supernatants containing equal amount of protein were incubated with streptavidin beads to immunoprecipitate the biotinylated proteins (Martin and Henley, 2004; Winterstein et al., 2008) . After extensive washes in extraction buffer, proteins were eluted from the streptavidin beads by heating at 65°C in Laemmli sample buffer and then were analyzed by SDS-polyacrylamide gel electrophoresis followed by Western blot analysis using a homemade antibody against GPR17 (1:1000) (Lecca et al., 2008; Fumagalli et al., 2011) . The primary antibody was detected using anti-rabbit IgG light chains conjugated to peroxidase (diluted 1:50,000). The peroxidase was detected using a chemiluminescent substrate (PerkinElmer Life and Analytical Sciences).
Data Analysis. A nonlinear multipurpose curve-fitting program, Prism (GraphPad Software Inc., San Diego, CA), was used for the binding data analysis of intracellular cAMP and [
35 S]GTP␥S; in addition, the EC 50 values were derived. Data are reported as the means Ϯ S.E.M. of three or four different experiments (performed in duplicate). Statistical analyses of binding data were performed using a one-way analysis of variance study followed by the Bonferroni test for repeated measurements. Differences were considered statistically significant when P Ͻ 0.05. The densitometric analysis of immunoreactive bands was performed using the ImageJ program (National Institutes of Health, Bethesda, MD).
Results
Expression Profile of 1321N1 Cells. Because the GPR17 ligands UDP-glucose and LTD 4 also activate P2Y 14 R (Das et al., 2010) and CysLTRs (Lynch et al., 1999; Takasaki et al., 2000) , the expression profile and stability of these receptors were evaluated in 1321N1 cells transfected with hGPR17. Reverse transcription (RT)-PCR analysis, performed using specifically designed primers for various cloned receptors, revealed that fragments sizes corresponded to the expected amplified products for GPR17 [891 base pair (bp)] and P2Y 14 (102 bp) even if to a lesser extent. No amplification products were observed using specific primers for both CysLT 1 (479 bp) and CysLT 2 (370 bp) (Fig. 1) .
Interaction between Purinergic and cysLT GPR17 Binding Sites. To detect interactions between nucleotides and cysLTs in GPR17-expressing cells, an analysis of [ 35 S]GTP␥S binding was performed. This assay was based on the fact that GPR stimulation by agonists results in increased binding of GTP to G proteins, which can be quantified by measuring [
35 S]GTP␥S binding to purified membranes (Marteau et al., 2003) . This assay has been used widely for the characterization of GPR17 responses by testing the increase of [
35 S]GTP␥S binding by exogenously added agonists in transfected cells (Ciana et al., 2006; Lecca et al., 2008; Pugliese et al., 2009; Temporini et al., 2009; Calleri et al., 2010 results from the interaction experiments demonstrate that LTD 4 , at two concentrations (one corresponding to its EC 50 value and the other one 10-fold over it), was able to induce a leftward shift of the UDP-glucose dose-response curve, causing a significant decrease in the UDP-glucose EC 50 value from 8.8 Ϯ 0.5 M to 176.8 Ϯ 11.2 nM (P Ͻ 0.001) and 180.9 Ϯ 14.0 nM (P Ͻ 0.001), respectively ( Fig. 2A ; Supplemental Fig. 1A ). These results demonstrate that LTD 4 increased the potency of UDP-glucose toward GPR17. In a similar manner, UDP-glucose, at two concentrations (one corresponding to its EC 50 value and the other one 10-fold over it), was able to enhance the LTD 4 -induced response, causing a leftward shift of the LTD 4 dose-response curve and an increase in its potency ( Fig. 2B; Supplemental Fig. 1B ). In particular, the LTD 4 EC 50 value significantly decreased from 9.06 Ϯ 0.75 to 0.33 Ϯ 0.02 nM (P Ͻ 0.001) and 0.32 Ϯ 0.01 nM (P Ͻ 0.001), respectively. In this case, an increase of the maximal effect also was observed (Fig. 2B) . The activation of GPR17 by either purinergic or cysLT ligands was speculated to induce a change in the receptor conformational state, enhancing the functional responsiveness of either class of endogenous ligands. Both agonists did not induce any significant stimulation of [ 35 S]GTP␥S binding in pcDNA 3.1-transfected cells, demonstrating that their effects were mediated specifically by GPR17 activation (data not shown).
To verify if two distinct binding sites (one for nucleotides and the other for cysLTs) were present on GPR17 (Parravicini et al., 2008 , the effects of the CysLT antagonist (montelukast) and the purinergic antagonist (cangrelor) were tested on the LTD 4 -and UDP-glucose-induced responses, respectively. Montelukast inhibited LTD 4 -mediated responses with an IC 50 value of 23.0 Ϯ 1.4 nM that was comparable with that from previous studies (Ciana et al., 2006) . This CysLT antagonist also was able to partially impair UDP-glucose-mediated responses with a potency in the micromolar range (IC 50 ϭ 1.10 Ϯ 0.65 M), although the purinergic agonist effects were not abolished completely (Fig. 3A) . Cangrelor antagonized LTD 4 -and UDPglucose-mediated responses with a potency in the nanomolar and sub-nanomolar ranges (IC 50 ϭ 104.0 Ϯ 7.5 and 0.81 Ϯ 0.05 nM), respectively (Fig. 3B) . As demonstrated for montelukast, the antagonistic effect of cangrelor toward LTD 4 was not complete. These data suggest that montelukast and cangrelor act as allosteric modulators for the purinergic and cysLT sites, respectively.
Homologous Desensitization/Resensitization of GPR17. To verify the kinetics and the extent of agonist-induced GPR17 desensitization, the cAMP assay was used. Previous data on both recombinant (Ciana et al., 2006) and native GPR17 (Fumagalli et al., 2011) have shown that, as expected for a G i -coupled receptor, GPR17 inhibits adenylyl cyclase activity and cAMP formation. Therefore, the activation of GPR17 can be studied by assessing the abilities of its agonists to inhibit the cAMP formation stimulated by the direct adenylyl cyclase activator FK (Fumagalli et al., 2011) . As a first step, 1321N1 cells were treated at different time points (5-90 min) with 10 nM LTD 4 or 10 M UDP-glucose. Cells then were washed with 400 l of saline buffer, and the cAMP assay was performed, as described above. Figure 4 shows that, at submaximal concentrations, both UDP-glucose (Fig.  4A ) and LTD 4 (Fig. 4B ) decreased GPR17 responses after an initial challenge with the same concentration of either UDPglucose or LTD 4 . These effects occurred in a time-dependent manner, resulting in an almost complete inhibition (Ͼ85%) of GPR17 activation after 90 min of preincubation with either agonist. The two agonists induced homologous desensitization of GPR17 with a similar kinetics. In a different set of experiments, the maximal percentage reduction of the UDP- glucose and LTD 4 responses after homologous desensitization ranged from 77 to 83% and from 78 to 89%, respectively.
Cells then were pretreated with graded UDP-glucose or LTD 4 concentrations for 90 min (the time at which maximal desensitization had been observed with the experiments described in Fig. 4) , and after the agonist was removed and the cells were washed, GPR17 responsiveness was measured by assessing the FK-stimulated cAMP response in the presence of either 10 M UDP-glucose or 10 nM LTD 4 , respectively. The results demonstrated that responses to both UDP-glucose (Fig. 5A ) and LTD 4 (Fig. 5B) were markedly reduced after a 90-min initial exposure to either agonist. The loss of GPR17 responsiveness was clearly dependent on the agonist concentration used for the initial challenge, with a minor loss of response at low agonist concentrations and an almost total loss of responsiveness in cells that had been preincubated with the highest UDP-glucose (100 M) or LTD 4 (100 nM) concentration.
To assess whether the agonist-induced loss of GPR17 responsiveness could be reverted by placing cells in agonistfree medium, a time course recovery rate analysis of the receptor functionality was performed after LTD 4 -or UDPglucose-induced desensitization. Thus, for both UDP-glucose and LTD 4 , an exposure time and agonist concentration were chosen at the maximal values observed for the desensitization, based on data reported in Figs. 5 and 6. Thus, cells were incubated for 90 min with UDP-glucose (100 M) and then washed and maintained in agonist-free medium for various times periods (30 -120 min). After each wash-out period, GPR17 responsiveness on cAMP assays was assessed by incubating cells with FK and 10 M UDP-glucose. Results showed that, after UDP-glucose-induced desensitization, the GPR17 response to the uracil nucleotides was restored completely after 90 min. The recovery of responsiveness was gradual and time-dependent, with a kinetics trend typical of that of a GPR (Fig. 6A) .
To evaluate the recovery of GPR17 functional responsiveness to cysLTs, cells were incubated for 90 min with 100 nM LTD 4 , washed out, and maintained in agonist-free medium for the indicated times (30 -120 min). After each wash-out period, GPR17 responsiveness on the cAMP assay was assessed by incubating cells with FK and 10 nM LTD 4 . Results indicated that, after LTD 4 -induced desensitization, recovery of GPR17 responsiveness to this cysLT occurred with kinetics values that were basically similar to those observed after UDP-glucose, although the resensitization seemed complete within 60 min (Fig. 6B) .
Heterologous Desensitization/Resensitization of GPR17. To investigate the existence of the cross-desensitization between the two putative purinergic and cysLT sites on GPR17, the GPR17 responsiveness to UDP-glucose was measured after an initial challenge with LTD 4 and vice versa. Figure 7B shows that UDP-glucose-induced responses were totally unaffected by a prior 90-min challenge with different LTD 4 concentrations, demonstrating that activation of the putative cysLT binding site on GPR17 was not able to influence the functionality of the GPR17 purinergic binding site, at least in 1321N1 cells.
In contrast, after a 90-min treatment with UDP-glucose, a modest but statistically significant decrease in the LTD 4 -mediated response was detected, especially at the highest UDP-glucose concentrations used (Fig. 7A) . In a different set of experiments, the maximal percentage reduction of the LTD 4 response after UDP-glucose cell treatments ranged from 52 to 74%.
It is clear from these data that the purinergic ligand was able to partially mediate a heterologous regulation of the putative cysLT binding site on GPR17, whereas the cysLT GPR17 ligand did not affect the functional responses mediated by the purinergic binding site.
To assess the recovery rate of GPR17 responsiveness to cysLT ligands, after heterologous desensitization, cells were incubated for 90 min with UDP-glucose (100 M), washed with saline buffer, and then maintained in agonist-free medium for various time periods (30 -120 min). After each washout period, GPR17 responsiveness on cAMP assays was assessed by incubating cells with FK in the presence of 10 nM LTD 4 . After heterologous desensitization, the kinetics of recovery for GPR17 functional responsiveness to LTD 4 occurred within 90 to 120 min (Fig. 8A) . In parallel, GPR17 functional response to UDP-glucose after LTD 4 cell treat- Fig. 6 . Functional resensitization of GPR17 after the induction of homologous desensitization. Cells were desensitized by incubation for 90 min with either 100 M UDP-glucose (A) or 100 nM LTD 4 (B) and were maintained in an agonist-free medium for different time intervals. Then, the restoration of GPR17 responsiveness on cAMP assays was assessed in the presence of 10 M FK and either 10 M UDP-glucose (A) or 10 nM LTD 4 (B), respectively. Data are expressed as the percentage of basal cAMP levels set to 100% and represent the means Ϯ S.E.M. of three separate experiments, each performed in duplicate. ‫,ءءء‬ P Ͻ 0.001 versus FK; #, P Ͻ 0.05; ##, P Ͻ 0.01; ###, P Ͻ 0.001 versus UDPglucose or LTD 4 . at ASPET Journals on April 9, 2017 jpet.aspetjournals.org Downloaded from ment was evaluated during all of the time periods of the cell washout. Cells were incubated for 90 min with LTD 4 (100 nM), washed with saline buffer, and then maintained in agonist-free medium for various times (30 -120 min). After each wash-out period, GPR17 responsiveness on cAMP assays was assessed by incubating cells with FK in the presence of 10 M UDP-glucose. The results (Fig. 8B) demonstrate that GPR17 remained completely responsive to UDP-glucose after the LTD 4 cell challenge and subsequent washout, confirming that LTD 4 does not affect UDPglucose-mediated responses.
GPR17 Intracellular Trafficking after Agonist Administration. To further investigate the mechanisms at the basis of GPR17 desensitization upon ligand binding and to specifically assess induction of receptor intracellular internalization, we decided to use biotinylation assays to follow receptor destiny after agonist exposure. To this purpose, receptors on the cell plasma membrane surface were labeled with a disulfide-containing biotinylating reagent under conditions that prevent receptor trafficking (incubation of the cells at 4°C). After being washed, cells were extracted either immediately or after biotin stripping of cell surface proteins using a disulfide-reducing reagent (DTT). Extracts then were blotted with an anti-GPR17 antibody (Fig. 9A ). In the absence of DTT, a single band corresponding to an apparent molecular mass of approximately 55 kDa was detected. DTT treatment and biotin stripping from the plasma membrane resulted in the almost complete disappearance of this band (Fig. 9A) , demonstrating that, under these conditions, all of the receptors are at the cell surface.
Cell surface biotinylated cells then were incubated with or without agonists at 37°C (i.e., under conditions allowing receptor trafficking). After a 15-or 30-min incubation, cells were cooled, and the remaining surface biotin was stripped with DTT as described above. Exposure of cells to UDPglucose activated the endocytosis of GPR17, as shown by the fact that stimulated cells had more biotinylated internalized GPR17 than nonstimulated cells (constitutive internalization, white column in Fig. 9C ). Quantitative analysis of at least three independent experiments showed that, after cell treatment with UDP-glucose for 15 and 30 min, 17.35 Ϯ 2.25% and 60.0 Ϯ 4.49% of surface biotinylated receptors, respectively, internalized inside cells. When cells were probed with LTD 4 , GPR17 underwent less efficient endocytosis: only 12.1 Ϯ 1.7% and 34.5 Ϯ 2.7% of the receptors were found internalized inside cells after agonist exposure for 15 and 30 min, respectively.
Discussion
Data from our group obtained from a number of different assays, such as [
35 S]GTP␥S binding assays (Ciana et al., 2006; Lecca et al., 2008; Calleri et al., 2010) , adenylyl cyclase assays (Ciana et al., 2006; Fumagalli et al., 2011) , frontal affinity chromatography-mass spectrometry (Temporini et al., 2009; Calleri et al., 2010) , whole-cell patch-clamp recording (Pugliese et al., 2009) , and extracellular signal-regulated kinase 1/2 and p38 phosphorylation , have shown that heterologously expressed GPR17 is responsive to two classes of ligands: uracil nucleotides and cysLTs (Ciana et al., 2006; Pugliese et al., 2009 ). This pharmacological profile also has been confirmed recently in two cell systems that natively express GPR17 by using some of the assays mentioned above as well as survival and cell differentiation assays Fumagalli et al., 2011) . However, the "dual" pharmacological profile of GPR17 remains to be confirmed because of conflicting data that have been reported. Recently, the purinergic component of GPR17 has been confirmed by another independent group (BennedJensen and Rosenkilde, 2010). Using both [
35 S]GTP␥S binding and cAMP response element-binding protein reporter assays, these authors have shown that UDP-glucose, UDPgalactose, and UDP activated human recombinant GPR17 in a concentration-dependent manner with EC 50 values in the micromolar range, which closely match those previously reported by us. These authors also have shown that GPR17 is not activated, internalized, or bound by cysLTs (BennedJensen and Rosenkilde, 2010) .
In contrast, results from in vitro recombinant systems have suggested that GPR17 also may act as a direct negative regulator of the CysLT 1 receptor response to LTD 4 via the formation of receptor-receptor dimers, an action that apparently does not require GPR17 activation by endogenous li- jpet.aspetjournals.org gands (Maekawa et al., 2009) . It may be that GPR17 can act as either a ligand-dependent or a ligand-independent pathway, depending on the specific cellular system and specific pathophysiological conditions. In this study, we confirmed by using both [ 35 S]GTP␥S binding and adenylyl cyclase assays that GPR17 is activated by uracil nucleotides and cysLTs. To determine the functional interactions between purinergic and cysLT-mediated responses, [
35 S]GTP␥S binding assays were used to investigate the reciprocal regulation between UDP-glucose and LTD 4 in mediating GPR17 coupling to G proteins in 1321N1 GPR17-transfected cells. Evidence was produced that demonstrates that UDP-glucose was able to enhance LTD 4 -induced GPR17 G protein coupling and vice versa. Thus, the activation of GPR17 by either purinergic or cysLT ligands induced a change in receptor conformational state that enhanced the functional responsiveness of either class of endogenous ligands. Analysis of agonist dose-response curves suggested that the modulatory effect between the two classes of GPR17 agonists occurs by an allosteric mechanism that may involve 1) two distinct binding sites on the same proteins or 2) two different proteins interacting on the plasma membrane. By RT-PCR, 1321N1 cells were demonstrated to express P2Y 14 R at low levels and not to express CysLTRs. In pcDNA 3.1-transfected cells, no functional responses to either UDP-glucose or LTD 4 were observed. These data suggest that, in 1321N1 cells, 1) P2Y 14 R, although expressed at low levels, is not involved in the functional response to sugar nucleotides (Communi et al., 2001) and 2) LTD 4 -evoked responses cannot be ascribed to the activation of any CysLTR subtypes in these cells.
This allosteric interaction between purinergic and cysLT ligands also was confirmed by data obtained using antagonists toward the two classes of GPR17 ligands. Montelukast and cangrelor, antagonists for the cysLT and purinergic sites, respectively, partially prevented the responses evoked by UDP-glucose and LTD 4 , with an IC 50 value not comparable with the affinity of these ligands for the homologous site. These data suggest that montelukast and cangrelor act as allosteric antagonists for purinergic and leukotriene sites on GPR17. These data were in line with data previously reported in the literature. In 1321N1 cells heterologously expressing human P2Y 1,2,4,6 Rs, CysLT 1 antagonists inhibited both P2YR agonist-induced activation of phospholipase C and intracellular Ca 2ϩ mobilization but in an insurmountable manner. These data demonstrated that CysLT 1 antagonists can interact functionally with the signaling pathways of P2YRs via an allosteric mechanism that did not involve direct interaction of the two receptors at the membrane level (Mamedova et al., 2005) . Despite the fact that nucleotides and cysLTs originated from totally independent metabolic pathways, several results suggest important functional interactions between the two families of signaling molecules and their receptors. P2Y 12 R has been found to be promiscuously activated by both nucleotides and LTE 4 (Nonaka et al., 2005) , further underlying the close relationship between the two families.
Having demonstrated that the two classes of GPR17 ligands modulate each other's responses, we then investigated the cross-talk between the two classes of ligands in inducing receptor desensitization. To do so, we took advantage of a cAMP assay that is typically used for this type of study.
GPR17 homologous and heterologous desensitization induced by purinergic and cysLT ligands were characterized, and the recovery of receptor responsiveness was determined after agonist removal.
The results indicate that both purinergic and cysLT agonists (i.e., both UDP-glucose and LTD 4 ) induce time-and concentration-dependent homologous receptor desensitization with kinetics comparable for both classes of ligands. After induction of desensitization and cell washout, receptor responsiveness was recovered (resensitization) with comparable kinetics for UDP-glucose and LTD 4 .
The heterologous desensitization between the purinergic and the cysLT GPR17 sites also was investigated. The results show that the activation of the GPR17 purinergic site by UDP-glucose induced a partial heterologous desensitization of LTD 4 -mediated responses with a kinetic value comparable with that observed for the homologous desensitization. In contrast, the activation of GPR17 with LTD 4 did not induce desensitization of UDP-glucose-mediated responses. These results were in line with data reported by Capra et al. (2005) , who showed that activation of P2YRs with extracellular nucleotides in dU937 cells induced heterologous desensitization of CysLT 1 but not receptor trafficking or internalization. In contrast, LTD 4 -induced CysLT 1 activation had no effect on P2YR responses, suggesting that the latter have a hierarchy in producing desensitizing signals .
After heterologous desensitization of cysLT responses, resensitization of signal occurred with kinetics slightly slower than that obtained in homologous desensitization studies and comparable with the resensitization kinetics typical of that of the purinergic site.
Because internalization of receptors also plays a role in receptor desensitization and leads to receptor endocytosis into vesicles and subsequent resensitization upon recycling of vesicles to the plasma membrane (Ferguson and Caron, 1998), we evaluated GPR17 internalization after agonist challenge. Results demonstrate that both agonists induce a time-dependent internalization of GPR17 receptors at the cell surface: the percentage of internalized receptors appeared to be higher after cell treatment with UDP-glucose with respect to that after cell treatment with LTD 4 . These differences in agonist-mediated internalization may account for the subtle differences observed in the kinetics of receptor recycling. We speculate that LTD 4 induces a lower degree of receptor internalization that allows a more rapid recycling of receptors to the plasma membrane and a quicker functional recovery. Of course, mechanisms other than receptor internalization also could also contribute to GPR17 desensitization, but the present data represent the first molecular demonstration that GPR17 can undergo agonistinduced down-regulation by intracellular endocytosis as expected for a GPR.
The determination of the regulatory mechanisms controlling GPR17 responses over time was pivotal to clarify the role of GPR17 in the differentiation of OPCs, which natively express this receptor at very high levels (Lecca et al., 2008; Chen et al., 2009; Fumagalli et al., 2011) . The pharmacological manipulation of GPR17 with its ligands has been shown to foster the progression of precursor cells toward mature myelinating cells, which no longer express the receptor. Loss of GPR17 at a relatively advanced differentiation state seems to be a prerequisite to allow the cells to proceed to terminal maturation, because the forced expression of GPR17 at later stages of OPC differentiation in a transgenic mouse line prevented myelination and induced precocious death (Chen et al., 2009 ). On the basis of the present data, we speculate that, by binding to GPR17, receptor endogenous ligands induce receptor desensitization and removal from the cell membrane, with subsequent internalization and degradation, and that this event may contribute to the physiological loss of GPR17 that has been demonstrated to occur during OPC maturation.
